logo
Plus   Neg
Share
Email

Leggett & Platt Updates FY18 Outlook - Quick Facts

Leggett & Platt (LEG) announced, for 2018, continuing operations EPS is now expected to be $2.60-$2.80, a $0.05 per share reduction from the prior range of $2.65-$2.85. The company said the decrease is due to the impact from continued steel cost inflation and the pricing lag the company experiences in recovering higher costs. EPS guidance assumes an approximate 22% tax rate.

For 2018, the company continues to expect that sales growth will lead to improved earnings. Sales are now expected to be $4.3-$4.4 billion, an increase of 9-12% versus 2017, and $100 million above the prior range of $4.2-$4.3 billion due to continued steel inflation. Volume growth is expected to be in the mid-single digits,

First-quarter earnings were $0.57 per share, down 8% versus the $0.62 per share earned in first quarter 2017, primarily from higher raw material costs. First quarter sales were $1.03 billion, an increase of 7% versus first quarter 2017. Same location sales grew 6%, for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
RELATED NEWS
Follow RTT